Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma

References

• Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 2013; 144:888 - 902; http://dx.doi.org/10.1053/j.gastro.2013.02.032; PMID: 23485860
   PubMed Web of Science ®Google Scholar
• Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43:515 - 24; http://dx.doi.org/10.1002/hep.21068; PMID: 16496320
   PubMed Web of Science ®Google Scholar
• Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, Rullier A, Cubel G, Couchy G, Imbeaud S, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007; 46:740 - 8; http://dx.doi.org/10.1002/hep.21743; PMID: 17663417
   PubMed Web of Science ®Google Scholar
• Bluteau O, Jeannot E, Bioulac-Sage P, Marqués JM, Blanc JF, Bui H, Beaudoin JC, Franco D, Balabaud C, Laurent-Puig P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002; 32:312 - 5; http://dx.doi.org/10.1038/ng1001; PMID: 12355088
   PubMed Web of Science ®Google Scholar
• Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, Izard T, Balabaud C, Bioulac-Sage P, Zucman-Rossi J. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009; 457:200 - 4; http://dx.doi.org/10.1038/nature07475; PMID: 19020503
   PubMed Web of Science ®Google Scholar
• Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, Nault JC, Izard T, Bioulac-Sage P, Couchy G, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 2011; 208:1359 - 66; http://dx.doi.org/10.1084/jem.20110283; PMID: 21690253
   PubMed Web of Science ®Google Scholar
• Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, Tran Van Nhieu J, Saint-Paul MC, De Muret A, Redon MJ, Buffet C, et al. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol 2012; 56:184 - 91; http://dx.doi.org/10.1016/j.jhep.2011.07.018; PMID: 21835143
   PubMed Web of Science ®Google Scholar
• Calderaro J, Labrune P, Morcrette G, Rebouissou S, Franco D, Prévot S, Quaglia A, Bedossa P, Libbrecht L, Terracciano L, et al. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol 2013; 58:350 - 7; http://dx.doi.org/10.1016/j.jhep.2012.09.030; PMID: 23046672
   PubMed Web of Science ®Google Scholar
• Chun YS, Calderaro J, Zucman-Rossi J. Synchronous hepatocellular carcinoma and Castleman’s disease: the role of the interleukin-6-signaling pathway. Hepatology 2012; 56:392 - 3; http://dx.doi.org/10.1002/hep.25857; PMID: 22611056
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798 - 809; http://dx.doi.org/10.1038/nrc2734; PMID: 19851315
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15:103 - 13; http://dx.doi.org/10.1016/j.ccr.2009.01.001; PMID: 19185845
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, Scheller J, Rose-John S, Kado S, Takada T. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2010; 184:1543 - 51; http://dx.doi.org/10.4049/jimmunol.0801217; PMID: 20042582
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, Malki S, Alderman BM, Grail D, Hollande F, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002; 8:1089 - 97; http://dx.doi.org/10.1038/nm763; PMID: 12219085
   PubMed Web of Science ®Google Scholar
• Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003; 101:2940 - 54; http://dx.doi.org/10.1182/blood-2002-04-1204; PMID: 12480704
   PubMed Web of Science ®Google Scholar
• Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269:199 - 225; http://dx.doi.org/10.1016/j.canlet.2008.03.009; PMID: 18479807
   PubMed Web of Science ®Google Scholar
• Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett 2010; 292:197 - 207; http://dx.doi.org/10.1016/j.canlet.2009.12.003; PMID: 20053498
   PubMed Web of Science ®Google Scholar
• Michaud-Levesque J, Bousquet-Gagnon N, Béliveau R. Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. Exp Cell Res 2012; 318:925 - 35; http://dx.doi.org/10.1016/j.yexcr.2012.02.017; PMID: 22394507
   PubMed Web of Science ®Google Scholar
• Miyamoto N, Sugita K, Goi K, Inukai T, Lijima K, Tezuka T, Kojika S, Nakamura M, Kagami K, Nakazawa S. The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2001; 15:1758 - 68; http://dx.doi.org/10.1038/sj.leu.2402260
   PubMed Web of Science ®Google Scholar
• Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44:694 - 8; http://dx.doi.org/10.1038/ng.2256; PMID: 22561517
   PubMed Web of Science ®Google Scholar
• Amaddeo G, Guichard C, Imbeaud S, Zucman-Rossi J. Next-generation sequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors. Oncoimmunology 2012; 1:1612 - 3; http://dx.doi.org/10.4161/onci.21480; PMID: 23264911
   PubMed Web of Science ®Google Scholar
• Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003; 300:2101 - 4; http://dx.doi.org/10.1126/science.1083901; PMID: 12829785
   PubMed Web of Science ®Google Scholar
• Bravo J, Staunton D, Heath JK, Jones EY. Crystal structure of a cytokine-binding region of gp130. EMBO J 1998; 17:1665 - 74; http://dx.doi.org/10.1093/emboj/17.6.1665; PMID: 9501088
   PubMed Web of Science ®Google Scholar
• Timmermann A, Pflanz S, Grötzinger J, Küster A, Kurth I, Pitard V, Heinrich PC, Müller-Newen G. Different epitopes are required for gp130 activation by interleukin-6, oncostatin M and leukemia inhibitory factor. FEBS Lett 2000; 468:120 - 4; http://dx.doi.org/10.1016/S0014-5793(00)01205-9; PMID: 10692570
   PubMed Web of Science ®Google Scholar
• Pflanz S, Kurth I, Grötzinger J, Heinrich PC, Müller-Newen G. Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation. J Immunol 2000; 165:7042 - 9; PMID: 11120832
   PubMed Web of Science ®Google Scholar
• Schmitz J, Weissenbach M, Haan S, Heinrich PC, Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 2000; 275:12848 - 56; http://dx.doi.org/10.1074/jbc.275.17.12848; PMID: 10777583
   PubMed Web of Science ®Google Scholar
• Mohr A, Chatain N, Domoszlai T, Rinis N, Sommerauer M, Vogt M, Müller-Newen G. Dynamics and non-canonical aspects of JAK/STAT signalling. Eur J Cell Biol 2012; 91:524 - 32; http://dx.doi.org/10.1016/j.ejcb.2011.09.005; PMID: 22018664
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115:3109 - 17; http://dx.doi.org/10.1182/blood-2009-04-214957; PMID: 20130243
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. N Engl J Med 2012; 366:787 98; http://dx.doi.org/10.1056/NEJMc1203704; PMID: 22621633
   PubMed Web of Science ®Google Scholar
• Edwards J. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opin Investig Drugs 2010; 19:605 - 14; http://dx.doi.org/10.1517/13543781003789388; PMID: 20367532
   PubMed Web of Science ®Google Scholar
• Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 2008; 68:7283 - 92; http://dx.doi.org/10.1158/0008-5472.CAN-07-6246; PMID: 18794115
   PubMed Web of Science ®Google Scholar
• Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317:121 - 4; http://dx.doi.org/10.1126/science.1140485; PMID: 17615358
   PubMed Web of Science ®Google Scholar
• Schütt A, Zacharias M, Schneider N, Horn S, Grötzinger J, Rose-John S, Schmidt-Arras D. gp130 activation is regulated by D2-D3 interdomain connectivity. Biochem J 2013; 450:487 - 96; http://dx.doi.org/10.1042/BJ20121660; PMID: 23294003
   PubMed Web of Science ®Google Scholar
• Streetz KL, Luedde T, Manns MP, Trautwein C. Interleukin 6 and liver regeneration. Gut 2000; 47:309 - 12; http://dx.doi.org/10.1136/gut.47.2.309; PMID: 10896929
   PubMed Web of Science ®Google Scholar
• Sommer J, Effenberger T, Volpi E, Waetzig GH, Bernhardt M, Suthaus J, Garbers C, Rose-John S, Floss DM, Scheller J. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem 2012; 287:13743 - 51; http://dx.doi.org/10.1074/jbc.M111.349167; PMID: 22523320
   PubMed Web of Science ®Google Scholar
• Bioulac-Sage P, Cubel G, Balabaud C, Zucman-Rossi J. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis 2011; 31:91 - 103; http://dx.doi.org/10.1055/s-0031-1272837; PMID: 21344354
   PubMed Web of Science ®Google Scholar
• Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, Laurent C, Blanc JF, Cubel G, Trillaud H, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50:481 - 9; http://dx.doi.org/10.1002/hep.22995; PMID: 19585623
   PubMed Web of Science ®Google Scholar
• Coqueret O, Gascan H. Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. J Biol Chem 2000; 275:18794 - 800; http://dx.doi.org/10.1074/jbc.M001601200; PMID: 10764767
   PubMed Web of Science ®Google Scholar